[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511476":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":12,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":12,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":12,"overallStatus":38,"whyStopped":12,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University Hospital, Angers","OTHER_GOV",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"control group","NO_INTERVENTION","Patients will be ask not to use any OSAS treatment during the 2 weeks of the study (after the CPAP withdrawal)",null,{"label":14,"type":15,"description":16,"interventionNames":17},"mandibular advancement device","EXPERIMENTAL","Patients will be asked to use mandibular advancement device during the 2 weeks CPAP withdrawal",[18],"Device: Mandibular advancement device treatment",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DEVICE","Mandibular advancement device treatment","a titratable thermoplastic mandibular advancement device will be proposed to patient in the experimental group during the 2 weeks of CPAP withdrawal.",[14],[26],{"name":27,"affiliation":5,"role":28},"wojciech Trzepizur, MD PHD","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":12,"email":34},"wojciech trzepizur, MD PHD","CONTACT","+3380575272","wotrezpizur@chu-angers.fr",[36],{"facility":37,"status":38,"city":39,"state":12,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Angers University Hospital","RECRUITING","Angers","49100","France","FR",{"type":44,"coordinates":45},"Point",[46,47],-0.55202,47.47156,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":52,"phoneExt":12,"email":53},"Wojciech Trzepizur, MD Ph D","+33680575272","wotrzepizur@chu-angers.fr",{"type":55,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100511476","impact-of-the-mandibular-advancement-device-on-sleep-apnea-during-cpap-withdrawal-100511476",false,"NCT05939934","Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal","Impact of the Mandibular Advancement Device on Sleep Apnea Syndrome During Discontinuation of Treatment With Continuous Positive Airway Pressure: Randomized Controlled Trial","ORTAP","Inclusion Criteria:\n\n* Patient accepting MAD treatment\n* Patient with an apnea-hypopnea index (AHI) greater than 15 events per hour on the initial recording\n* Patient with excessive daytime sleepiness during initial treatment (ESE\\>10)\n* Patient treated for more than 12 months by CPAP with average compliance greater than 5 hours per night\n\nExclusion Criteria:\n\n* Initial severe daytime sleepiness characterized\n* OSAS with ≥ 5 central apneas per hour of sleep at baseline recording\n* Previously diagnosed severe cardiac and\u002For respiratory pathology:\n* Body mass index ≥ 35 kg\u002Fm2\n* Known contraindication to OAM treatment","ALL","18 Years","75 Years",{"count":68,"type":69},40,"ESTIMATED","INTERVENTIONAL",[72],"NA","Obstructive sleep apnea hypopnea syndrome (OSAS) is a frequent disease with neuropsychological and cardiovascular (CV) consequences. Continuous positive pressure (CPAP), the main treatment for OSAHS, is effective on the majority of symptoms but restrictive, which can promote non-compliance. Treatment interruptions are often observed in connection with intercurrent events such as nasal obstructions or even when patients are on the move. However, randomized trials have shown that stopping treatment, even for a short time, leads to a recurrence of symptoms and significant CV disturbances (increase in blood pressure, endothelial dysfunction, cardiac repolarization disorders). It seems important to consider strategies that promote therapeutic continuity. The mandibular advancement device (MAD) is an interesting tool in this regard. MAD is as effective as CPAP on symptoms and CV data. The investigators want to assess its effectiveness as a complementary treatment during treatment discontinuation on the main consequences of OSAHS.",[75,76],"Sleep Apnea, Obstructive","Endothelial Dysfunction","2026-03-31",{"date":79,"type":80},"2026-04-06","ACTUAL",{"date":82,"type":80},"2024-03-05",{"date":84,"type":69},"2026-11",{"name":5,"class":6},1]